AR008676A1 - Acidos beta-sulfonamido hidrosamicos como inhibidores de la metaloproteinasa de matriz y tace, uso de los mismos en la preparacion de unmedicamento y una composicion farmaceutica que los contienen - Google Patents
Acidos beta-sulfonamido hidrosamicos como inhibidores de la metaloproteinasa de matriz y tace, uso de los mismos en la preparacion de unmedicamento y una composicion farmaceutica que los contienenInfo
- Publication number
- AR008676A1 AR008676A1 ARP970104748A ARP970104748A AR008676A1 AR 008676 A1 AR008676 A1 AR 008676A1 AR P970104748 A ARP970104748 A AR P970104748A AR P970104748 A ARP970104748 A AR P970104748A AR 008676 A1 AR008676 A1 AR 008676A1
- Authority
- AR
- Argentina
- Prior art keywords
- tace
- disease
- eye
- inhibitors
- hydrosamic
- Prior art date
Links
- 239000002253 acid Substances 0.000 title abstract 3
- BFPSDSIWYFKGBC-UHFFFAOYSA-N chlorotrianisene Chemical compound C1=CC(OC)=CC=C1C(Cl)=C(C=1C=CC(OC)=CC=1)C1=CC=C(OC)C=C1 BFPSDSIWYFKGBC-UHFFFAOYSA-N 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 239000011159 matrix material Substances 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 229940124530 sulfonamide Drugs 0.000 title 1
- 102000043279 ADAM17 Human genes 0.000 abstract 2
- 108091007505 ADAM17 Proteins 0.000 abstract 2
- 102100031111 Disintegrin and metalloproteinase domain-containing protein 17 Human genes 0.000 abstract 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 abstract 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 abstract 2
- 230000033115 angiogenesis Effects 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 abstract 1
- 208000020084 Bone disease Diseases 0.000 abstract 1
- 206010006895 Cachexia Diseases 0.000 abstract 1
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
- 108060005980 Collagenase Proteins 0.000 abstract 1
- 102000029816 Collagenase Human genes 0.000 abstract 1
- 208000016192 Demyelinating disease Diseases 0.000 abstract 1
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 206010015943 Eye inflammation Diseases 0.000 abstract 1
- 108010026132 Gelatinases Proteins 0.000 abstract 1
- 102000013382 Gelatinases Human genes 0.000 abstract 1
- 208000031886 HIV Infections Diseases 0.000 abstract 1
- 208000037357 HIV infectious disease Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 206010060820 Joint injury Diseases 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 206010029113 Neovascularisation Diseases 0.000 abstract 1
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 abstract 1
- 206010037660 Pyrexia Diseases 0.000 abstract 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 abstract 1
- 206010038934 Retinopathy proliferative Diseases 0.000 abstract 1
- 206010040070 Septic Shock Diseases 0.000 abstract 1
- 206010052779 Transplant rejections Diseases 0.000 abstract 1
- 208000025865 Ulcer Diseases 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 150000007513 acids Chemical class 0.000 abstract 1
- 206010064930 age-related macular degeneration Diseases 0.000 abstract 1
- 208000022531 anorexia Diseases 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 abstract 1
- 210000000845 cartilage Anatomy 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 206010061428 decreased appetite Diseases 0.000 abstract 1
- 230000003412 degenerative effect Effects 0.000 abstract 1
- 208000024519 eye neoplasm Diseases 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 208000002780 macular degeneration Diseases 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 abstract 1
- 208000001491 myopia Diseases 0.000 abstract 1
- 230000004379 myopia Effects 0.000 abstract 1
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 abstract 1
- 210000000653 nervous system Anatomy 0.000 abstract 1
- 208000028169 periodontal disease Diseases 0.000 abstract 1
- 230000006785 proliferative vitreoretinopathy Effects 0.000 abstract 1
- 201000001474 proteinuria Diseases 0.000 abstract 1
- 230000036303 septic shock Effects 0.000 abstract 1
- 108091007196 stromelysin Proteins 0.000 abstract 1
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 abstract 1
- 230000000472 traumatic effect Effects 0.000 abstract 1
- 230000005748 tumor development Effects 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
- 230000036269 ulceration Effects 0.000 abstract 1
- 230000029663 wound healing Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Se relaciona con el descubrimiento de novedosos inhibidores no peptídicos de bajo peso molecular de las metaloproteinasas de matriz (por ejemplo,gelatinasas, estromelisinas y colagenasas) y de una enzima conversora de TNF- alfa (TACE, enzima de conversion de factor alfa de necrosis tumoral) que sonutiles para el tratamiento de enfermedades en las cuales intervienen estas enzimas, tales como la artritis, la metástasis y desarrollo de tumores, laangiogénesis, la ulceracion de tejidos, lacicatrizacion anormal de heridas, enfermedad periodontal, enfermedad osea, proteinuria, enfermedad de aneurismaaortico, pérdida degenerativa de cartílago posterior a lesion traumática de las articulaciones, enfermedades desmielinizantes del sistema nervioso, recha deinjertos, caquexia, anorexia, inflamacion, fiebre resistencia a la insulina, choque séptico, insuficiencia cardíaca congestiva, enfermedad inflamatoria delsistema nervioso central, enfermedad inflamatoria intestinal, infeccionpor HIV, degeneracion macular asociada a la edad, retinopatía diabética,vitreorretinopatía proliferativa, retinoopatía de la prematuridad, inflamacion ocular, queratocino, síndrome de Sjogre, miopía, tumores oculares,angiogénesis/neovascularizacion ocular. Los ácidos ortosulfonamido arihidroxámicos inhibidores de TACE y MMP están representados por la formula(I) en la cual la porcion de ácido hidroxámico y la porcion sulfonamido están unidas a los caarbonos adyacentes del grupo A donde: A es un grupoheterocíclico monocíclico no aromático de 5 a 7 miembros que tiene de 1 a 2 heteroátomos independientemente seleccionados entre N,O y S, optativamentesustituido por R1, R2, R3 y R4; un cicloalquilo C3-C7 que contiene O-2 enlaces dobles y está optativamente sustituido con R1, R2, R3 y R4 o -CHR6; Z es arilo
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72935996A | 1996-10-16 | 1996-10-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR008676A1 true AR008676A1 (es) | 2000-02-09 |
Family
ID=24930685
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP970104748A AR008676A1 (es) | 1996-10-16 | 1997-10-15 | Acidos beta-sulfonamido hidrosamicos como inhibidores de la metaloproteinasa de matriz y tace, uso de los mismos en la preparacion de unmedicamento y una composicion farmaceutica que los contienen |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP0934259B1 (es) |
| JP (1) | JP2001502326A (es) |
| KR (1) | KR20000049198A (es) |
| CN (1) | CN1105101C (es) |
| AR (1) | AR008676A1 (es) |
| AT (1) | ATE224364T1 (es) |
| AU (1) | AU736134B2 (es) |
| BR (1) | BR9712524A (es) |
| CA (1) | CA2268895A1 (es) |
| DE (1) | DE69715647T2 (es) |
| DK (1) | DK0934259T3 (es) |
| ES (1) | ES2184069T3 (es) |
| IL (1) | IL129149A (es) |
| NZ (1) | NZ335053A (es) |
| PT (1) | PT934259E (es) |
| WO (1) | WO1998016506A1 (es) |
| ZA (1) | ZA979236B (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2220004T3 (es) * | 1998-04-10 | 2004-12-01 | Pfizer Products Inc. | Derivados del acido ciclobutil-ariloxiarilsulfonilaminohidroxamico. |
| CA2333554A1 (en) * | 1998-06-17 | 1999-12-23 | Chu-Baio Xue | Cyclic hydroxamic acids as metalloproteinase inhibitors |
| US6313123B1 (en) | 1999-01-27 | 2001-11-06 | American Cyanamid Company | Acetylenic sulfonamide thiol tace inhibitors |
| US6277885B1 (en) | 1999-01-27 | 2001-08-21 | American Cyanamid Company | Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors |
| US6946473B2 (en) | 1999-01-27 | 2005-09-20 | Wyeth Holdings Corporation | Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors |
| US6340691B1 (en) | 1999-01-27 | 2002-01-22 | American Cyanamid Company | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors |
| US6762178B2 (en) | 1999-01-27 | 2004-07-13 | Wyeth Holdings Corporation | Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors |
| US6200996B1 (en) | 1999-01-27 | 2001-03-13 | American Cyanamid Company | Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors |
| US6753337B2 (en) | 1999-01-27 | 2004-06-22 | Wyeth Holdings Corporation | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors |
| US6358980B1 (en) | 1999-01-27 | 2002-03-19 | American Cyanamid Company | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors |
| US6225311B1 (en) | 1999-01-27 | 2001-05-01 | American Cyanamid Company | Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors |
| US6326516B1 (en) | 1999-01-27 | 2001-12-04 | American Cyanamid Company | Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors |
| WO2000046189A1 (en) * | 1999-02-02 | 2000-08-10 | Shionogi & Co., Ltd. | Sulfonamide derivatives having cyclic structures |
| CA2409615C (en) * | 2000-05-23 | 2010-08-24 | Osmonics, Inc. | Modified sulfonamide polymers |
| MXPA04004010A (es) | 2001-11-01 | 2004-07-23 | Wyeth Corp | Acidos hidroxamicos de aril sulfonamida alenicos como inhibidores de tace y metaloproteinasa de matriz. |
| PE20030701A1 (es) | 2001-12-20 | 2003-08-21 | Schering Corp | Compuestos para el tratamiento de trastornos inflamatorios |
| US7491718B2 (en) | 2002-10-08 | 2009-02-17 | Abbott Laboratories | Sulfonamides having antiangiogenic and anticancer activity |
| US20040157836A1 (en) * | 2002-10-08 | 2004-08-12 | Comess Kenneth M. | Sulfonamides having antiangiogenic and anticancer activity |
| AU2003304456A1 (en) | 2002-12-23 | 2005-03-16 | Wyeth Holdings Corporation | Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors |
| ATE449760T1 (de) * | 2004-03-22 | 2009-12-15 | Southern Res Inst | Nichtpeptidinhibitoren von matrixmetalloproteinasen |
| FR2947270B1 (fr) | 2009-06-30 | 2011-08-26 | Galderma Res & Dev | Nouveaux composes benzene-sulfonamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique |
| FR2947268B1 (fr) * | 2009-06-30 | 2011-08-26 | Galderma Res & Dev | Nouveaux composes benzene-sulfonamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique |
| US20140275108A1 (en) | 2013-03-15 | 2014-09-18 | Galderma Research & Development | Novel benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics |
| IL237852A0 (en) | 2015-03-19 | 2016-03-24 | Yeda Res & Dev | Antibodies against amphigoline, medical preparations containing them and their use |
| WO2017117130A1 (en) | 2015-12-28 | 2017-07-06 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Methods for inhibiting human immunodeficiency virus (hiv) release from infected cells |
| EP3199534B1 (en) | 2016-02-01 | 2018-09-05 | Galderma Research & Development | Benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine and cosmetics |
| BR112021006407A8 (pt) | 2018-10-04 | 2022-12-06 | Inst Nat Sante Rech Med | uso de inibidores do egfr para ceratodermas |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5455258A (en) * | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| CA2160139A1 (en) * | 1993-04-07 | 1994-10-13 | Richard Edward Galardy | Synthetic matrix metalloprotease inhibitors and uses thereof |
| US5672598A (en) * | 1995-03-21 | 1997-09-30 | The Procter & Gamble Company | Lactam-containing hydroxamic acids |
-
1997
- 1997-10-08 IL IL12914997A patent/IL129149A/xx not_active IP Right Cessation
- 1997-10-08 CA CA002268895A patent/CA2268895A1/en not_active Abandoned
- 1997-10-08 AT AT97912674T patent/ATE224364T1/de not_active IP Right Cessation
- 1997-10-08 DE DE69715647T patent/DE69715647T2/de not_active Expired - Fee Related
- 1997-10-08 KR KR1019990703296A patent/KR20000049198A/ko not_active Abandoned
- 1997-10-08 CN CN97180606A patent/CN1105101C/zh not_active Expired - Fee Related
- 1997-10-08 DK DK97912674T patent/DK0934259T3/da active
- 1997-10-08 NZ NZ335053A patent/NZ335053A/xx unknown
- 1997-10-08 AU AU49790/97A patent/AU736134B2/en not_active Ceased
- 1997-10-08 JP JP10518424A patent/JP2001502326A/ja not_active Ceased
- 1997-10-08 WO PCT/US1997/018170 patent/WO1998016506A1/en not_active Ceased
- 1997-10-08 BR BR9712524-5A patent/BR9712524A/pt not_active Application Discontinuation
- 1997-10-08 ES ES97912674T patent/ES2184069T3/es not_active Expired - Lifetime
- 1997-10-08 EP EP97912674A patent/EP0934259B1/en not_active Expired - Lifetime
- 1997-10-08 PT PT97912674T patent/PT934259E/pt unknown
- 1997-10-15 ZA ZA9709236A patent/ZA979236B/xx unknown
- 1997-10-15 AR ARP970104748A patent/AR008676A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| PT934259E (pt) | 2003-01-31 |
| EP0934259B1 (en) | 2002-09-18 |
| AU4979097A (en) | 1998-05-11 |
| WO1998016506A1 (en) | 1998-04-23 |
| BR9712524A (pt) | 1999-10-19 |
| CN1105101C (zh) | 2003-04-09 |
| EP0934259A1 (en) | 1999-08-11 |
| HK1020720A1 (en) | 2000-05-19 |
| IL129149A0 (en) | 2000-02-17 |
| JP2001502326A (ja) | 2001-02-20 |
| DE69715647T2 (de) | 2003-02-20 |
| DE69715647D1 (en) | 2002-10-24 |
| DK0934259T3 (da) | 2003-01-27 |
| ZA979236B (en) | 1999-07-15 |
| CA2268895A1 (en) | 1998-04-23 |
| NZ335053A (en) | 2000-10-27 |
| AU736134B2 (en) | 2001-07-26 |
| ES2184069T3 (es) | 2003-04-01 |
| KR20000049198A (ko) | 2000-07-25 |
| CN1240424A (zh) | 2000-01-05 |
| ATE224364T1 (de) | 2002-10-15 |
| IL129149A (en) | 2003-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR008676A1 (es) | Acidos beta-sulfonamido hidrosamicos como inhibidores de la metaloproteinasa de matriz y tace, uso de los mismos en la preparacion de unmedicamento y una composicion farmaceutica que los contienen | |
| AR009990A1 (es) | Acidos orto-sulfonamido heteroaril hidroxamicos biciclicos como inhibidores de la metaloproteinasa de matriz y tace, uso de dichos compuestos para prepararmedicamentos, y composiciones farmaceuticas que los contienen | |
| AR008677A1 (es) | Acidos orto-sulfonamido heteroaril hidroxamicos como inhibidores de la metalproteinasa de matriz y tace, uso de dichos compuestos para prepararmedicamentos y composicion farmaceutica que los contiene | |
| AR009382A1 (es) | Derivados de acidos orto-sulfonamido aril hidroxamicos como inhibidores de la metaloproteinasa de matriz y tace, composiciones que los contienen y uso delos mismos para la preparacion de un medicamento. | |
| RU2324684C2 (ru) | Пиримидиновые производные | |
| DE69713526D1 (de) | Lösliche prodrugs von paclitaxel | |
| ES2156421T3 (es) | Composiciones utiles para la transferencia de polinucleotidos terapeuticamente activos a una celula diana y su utilizacion en la terapia genica. | |
| NO174202C (no) | Analogifremgangsmåte for fremstilling av terapeutisk aktivt azainden-derivater | |
| ES2063011T3 (es) | Agentes antibacteriales de quinolonas y naftiridinas que contienen un alfa-aminoacido en la cadena lateral del 7-sustituyente. | |
| ES2328799T3 (es) | Compuestos de piridilcianoguanidina. | |
| UY27781A1 (es) | Compuestos químicos. | |
| NO20005912L (no) | Sulfonylsyre- eller sulfonylamino-N-(heteroaralkyl)- azaheterocyklylamidforbindelser | |
| ATE123944T1 (de) | Verwendung von trifluormethylphenyl- tetrahydropyridinen zur herstellung von arzneimitteln zur behandlung anxio-depressiver erkrankungen. | |
| ES2147629T3 (es) | Guanidinas de acido alquenilcarboxilico sustituidas con un grupo fluorofenilo como inhibidores del intercambio de na+/nh+, su procedimiento de preparacion y su uso como medicamento o agente diagnostico asi como el medicamento que las contiene. | |
| CN107151236B (zh) | 一种2,3-环氧丁二酰衍生物及其制备方法和用途 | |
| CN102695697A (zh) | 特别地用于医学用途的新型多功能肽酶抑制剂 | |
| AR022405A1 (es) | Derivados de acido piroglutamico y compuestos relacionados que inhiben la adhesion de leucocitos intermediada por vla-4, composiciones farmaceuticas y eluso de los mismos para la manufactura de agentes y de medicamentos | |
| SE7701187L (sv) | Nya piperazinderivat och sett att framstella desamma | |
| KR102042411B1 (ko) | 데커신 유도체를 포함하는 결핵 예방 또는 치료용 조성물 | |
| CN101648924A (zh) | 组蛋白去乙酰酶抑制剂异羟肟酸类化合物及其用途 | |
| JPS5649374A (en) | Novel 33aminoo11benzoxepin derivative* its manufacture and gastroointestinal movement trouble therapeutic drug containing it | |
| ES2376054T3 (es) | Simmondsin para uso como un inhibidor angiogenesis. | |
| EP0207483A3 (en) | Benzimidazoles, process for their preparation, medicaments containing them and intermediates | |
| MacNeal et al. | Conjoined action of penicillin and bacteriophages | |
| DE3684186D1 (de) | Verwendung von pharmaceutischen zusammensetzungen fuer die herstellung von arzneimitteln fuer die behandlung psychiatrischer stoerungen. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |